Composition containing probiotics for telomerase production

Abstract

A composition comprising a recombinant probiotic organism engineered to constitutively express an enzyme involved in maintaining telomere length, wherein the enzyme comprises a telomerase subunit, the genetic modification comprises an operon comprising a gene sequence encoding telomerase having a promoter recognized by the RNA polymerase of the probiotic organism and a genetic modification that induces the secretion of telomerase into the host organism, and the genetic modification of the telomerase gene sequence enhances the entry of the telomerase enzyme into the host organism's cells.

Description

Technical Field

[0001] The claimed embodiments generally relate to health supplements, and more specifically to compositions containing probiotics for enhancing the production of telomerase.

Background Art

[0002] The fields of longevity and health maintenance have long been of interest in the context of biomedical research, particularly cell aging and its impact on overall health. Central to the aging process is the progressive shortening of telomeres, the protective caps located at the ends of chromosomes, which occurs with each cell division. Telomere length is an important factor in cellular senescence, the point at which cells stop dividing. Therefore, maintaining or extending telomere length has gathered significant interest from the perspective of promoting health and potentially extending lifespan.

[0003] To date, approaches to regulating telomere length have mainly focused on direct intervention in genes, pharmaceuticals, and various lifestyle modifications, each with varying degrees of success and practicality. The enzyme telomerase has been identified as a major factor in maintaining telomere length, capable of adding telomeric DNA to the ends of chromosomes and thus counteracting the natural process of telomere shortening. However, an effective and safe method to enhance telomerase activity in humans has yet to be clearly elucidated.

[0004] Current strategies for maintaining telomere length face several challenges, including delivering therapeutic agents in an effective and safe manner, targeting the treatment to appropriate cells, and obtaining sustained telomerase activity without accompanying side effects. Furthermore, easily accessible, non-invasive, and lifestyle-compatible interventions are sought, but many current approaches do not adequately address this.

[0005] Prior art clearly demonstrates attempts to directly manipulate telomerase activity through gene therapy and pharmacological agents, but these methods often involve significant risks, such as an increased likelihood of carcinogenesis, as well as practical limitations in terms of delivery and action specificity. Furthermore, the use of synthetic compounds or highly engineered biological agents raises concerns regarding long-term safety and regulatory approval.

[0006] Therefore, prior art presents a clear and unmet need for innovative solutions that can safely and effectively regulate telomerase activity, thereby addressing the fundamental challenge of telomere shortening in cellular aging. [Overview of the project] [Problems that the invention aims to solve]

[0007] This summary is provided to introduce, in a simplified form, a selection of disclosed concepts, which are further described below in the detailed description, including the provided drawings. This summary is not intended to identify any major or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter. [Means for solving the problem]

[0008] The disclosed embodiments relate to compositions comprising recombinant probiotic organisms engineered to constitutively express an enzyme involved in maintaining telomere length, wherein the enzyme comprises a telomerase subunit, the genetic modification comprises an operon containing a promoter and a gene encoding telomerase that is recognized by the RNA polymerase of the probiotic organism, the bacteria comprises a genetic modification that induces the secretion of telomerase into the host organism, and the genetic modification of the telomerase gene sequence enhances the entry of the telomerase enzyme into the host organism's cells.

[0009] To achieve the above and related objectives, the claimed subject matter may be carried out in the forms shown in the accompanying drawings. However, it should be noted that these drawings are illustrative only and modifications may be made to the specific structures shown and described within the scope of the accompanying claims. The aforementioned and other features and advantages of the claimed embodiments will become apparent from the following more detailed description of the preferred embodiments shown in the accompanying drawings.

[0010] The accompanying drawings are incorporated into and constitute part of this specification and illustrate embodiments of the claimed subject matter, and together with the detailed description, serve to illustrate the principles of the disclosed embodiments. While the embodiments illustrated herein are currently preferred, it is understood that the claimed subject matter is not limited to the exact configurations and apparatus shown. [Brief explanation of the drawing]

[0011] [Figure 1] This figure shows a powder-form composition containing probiotics for enhancing telomerase production, according to one embodiment. [Figure 2] This figure shows a capsule-form composition containing probiotics for enhancing telomerase production, according to one embodiment. [Figure 3] This figure shows a capsule-form composition containing probiotics for enhancing telomerase production, according to one embodiment. [Figure 4] This figure shows various ready-to-eat compositions containing probiotics for enhancing telomerase production, according to one embodiment. [Modes for carrying out the invention]

[0012] The following detailed description refers to the accompanying drawings. Where possible, the same reference numerals are used in the drawings and the following detailed description to refer to identical or similar elements. While the disclosed embodiments may be described, modifications, adaptations, and other forms of implementation are also possible. For example, elements shown in the drawings may be replaced, added, or modified, and the methods described herein may be modified by replacing, rearranging, or adding additional steps or components to the disclosed methods and devices. Therefore, the following detailed description is not limited to the disclosed embodiments. Instead, the appropriate scope of the disclosed embodiments is defined by the accompanying claims.

[0013] The claimed embodiments described herein enhance the body's ability to combat aging, among other effects. The claimed embodiments represent a significant advance over prior art in the field of longevity and health maintenance, particularly addressing the challenge of telomere shortening, a critical factor in cellular aging. Conventional approaches to maintaining or extending telomere length have primarily focused on direct genetic interventions, pharmaceuticals, and various lifestyle modifications. While these methods offer several advantages, they have been limited by issues related to delivery, targeting, safety, and practicality. For example, gene therapies and pharmacological agents have faced obstacles due to potential carcinogenicity, difficulty in targeting specific cells, and the challenge of achieving sustained activity without side effects. Furthermore, reliance on synthetic compounds or highly engineered biological agents raises concerns regarding long-term safety and regulatory approval.

[0014] The claimed embodiments offer an innovative solution to combat telomere shortening by utilizing recombinant probiotic organisms engineered to constitutively express telomerase, an enzyme that adds DNA sequences to the ends of chromosomes. Unlike conventional methods, this approach provides a non-invasive, readily available, and potentially safer alternative to enhancing telomerase activity in humans. By incorporating genetic modifications into probiotic organisms already recognized for their health benefits, the claimed embodiments solve delivery and specificity problems by leveraging the natural mechanisms by which probiotics interact with and influence the host's biological systems. This ensures that the therapeutic agent, telomerase, is directly produced and secreted within the host organism, more effectively targeting cells and reducing the risk of side effects associated with other delivery methods.

[0015] Furthermore, the use of probiotics avoids the limitations associated with synthetic compounds and gene therapies, providing a solution that is more readily accepted by regulatory authorities and generally perceived as safe. The versatility of formulations, including options for incorporation into foods, beverages, or direct supplements, addresses the practicality and accessibility issues of conventional approaches, making it easier for individuals to incorporate this solution into their daily lives.

[0016] By addressing the fundamental challenge of telomere shortening with a novel probiotic-based strategy, the claimed embodiments not only overcome significant limitations of the prior art but also open up new approaches to promoting health and longevity. The claimed embodiments' approach to enhancing telomerase activity in a safe, effective, and user-friendly manner represents a significant advance in the fields of biomedical and longevity research.

[0017] Figure 1 shows a powder-form composition 100 containing probiotics for enhancing telomerase production, according to one embodiment. Figure 1 shows that the composition may be provided to consumers in powder form 100 in a container 102, which has a removable top 104 to provide access to the inside of the container. The powder may be ingested by mixing it with a liquid such as water or milk, or it may be added to solid food.

[0018] Figure 2 shows a formulation of composition 100 in capsule form containing probiotics for enhancing telomerase production according to one embodiment. Figure 2 shows that the composition may be provided to consumers in capsule form 200 in a container 202, which has a removable top 204 to provide access to the inside of the container.

[0019] Figure 3 shows a capsule-form composition 100 containing probiotics for enhancing telomerase production, according to one embodiment. Figure 3 shows that composition 100 is provided in a capsule 300 comprising a first portion 302 and a second portion 304, where composition 100 is shown to exist in powder form within the capsule. The design of the capsule 300, including its composition, shell thickness, and any special coatings, may affect the release rate and absorption characteristics of composition 100. Some capsules are designed for immediate release, while others are formulated for sustained release or delayed release to provide a longer-lasting effect.

[0020] Figure 4 shows a composition 100 in various ready-to-eat forms containing probiotics for enhancing telomerase production, according to one embodiment. Figure 4 shows that the composition can be provided in various ready-to-eat forms, where composition 100 is present, for example, in sour cream 402, fermented pickles 404, yogurt 406, and apple cider vinegar 408. Additional examples of ready-to-eat forms include brined olives, cheese, cottage cheese, fermented buttermilk, kefir, kimchi, kombucha, kumis, kvass, miso, natto, sauerkraut, tempeh, viili yogurt, and water kefir.

[0021] The claimed composition 100 represents a groundbreaking approach to promoting longevity and cellular health through the maintenance of telomere length. The claimed composition comprises genetically engineered probiotic organisms. These organisms are meticulously designed to constitutively express telomerase, a critical enzyme in telomere elongation and maintenance. Telomeres are protective caps at the ends of chromosomes and play a vital role in cellular aging by protecting chromosome ends from degradation. As cells divide, telomeres gradually shorten, leading to cellular senescence, i.e., the loss of the cell's ability to divide and grow. This process is a natural part of aging and is a major area of ​​interest for extending the health span and lifespan.

[0022] The genetically engineered probiotic organisms in the claimed composition are produced by recombinant DNA technology that enables the introduction of new genetic material. The introduced genetic modifications include an operon, which is a group of genes that function under the control of a single promoter. A promoter is a DNA sequence recognized by the organism's RNA polymerase and initiates the transcription of the gene it controls, in this case, the gene encoding telomerase. With this strategic modification, it is ensured that the probiotic continuously produces telomerase. Furthermore, the bacteria are engineered to secrete telomerase, facilitating its delivery into the host organism and promoting the maintenance of telomere length from within. It should be noted that the genetic modification of the telomerase gene sequence enhances the entry of the telomerase enzyme into the cells of the host organism.

[0023] RNA polymerase is an important enzyme found in all organisms and plays a fundamental role in the process of transcription, the first step of gene expression. During transcription, RNA polymerase reads the DNA template strand and synthesizes the complementary strand of RNA. This RNA strand can become messenger RNA (mRNA), transfer RNA (tRNA), or ribosomal RNA (rRNA) depending on the gene being transcribed. Each type of RNA has a specific function within the cell. mRNA functions as a template for protein synthesis during translation, tRNA transports amino acids to the ribosome for protein assembly, and rRNA forms the core of the ribosome structure and catalyzes protein synthesis.

[0024] The claimed compositions identify organisms belonging to various "genera," which are biological classification terms indicating a rank that groups species exhibiting common characteristics. Selected genera include Bacillus, Bifidobacterium, Enterococcus, Escherichia, and several other genera within the Lactobacillus group, each known for its health-promoting properties. The claimed compositions are further limited to specific species within these genera, such as Bacillus subtilis and Bifidobacterium bifidum, selected for their demonstrated safety and efficacy as probiotics.

[0025] The probiotic organisms in the claimed composition belong to a genus selected from Bacillus, Bifidobacterium, Enterococcus, Escherichia, Fructilactobacillus (formerly Lactobacillus), Lacticaseibacillus (formerly Lactobacillus), Lactiplantibacillus (formerly Lactobacilus), Lactobacillus, Lentilactobacillus (formerly Lactobacillus), Levilactobacillus (formerly Lactobacillus), Limosilactobacillus (formerly Lactobacillus), Loigolactobacillus (formerly Lactobacillus), Lactococcus (formerly Lactobacillus xylosus), Leuconostoc, Pediococcus, Saccharomyces, Streptococcus, Weissella (formerly Lactobacillus), Yarrowia.

[0026] The claimed composition includes the following species: Bacillus subtilis, Bacillus amyloliquefaciens, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Enterococcus faecalis, Enterococcus faecium, and Escherichia coli. coli), Fructilactobacillus fructivorans (formerly Lactobacillus fructivorans), Lacticaseibacillus casei (formerly Lactobacillus casei), Lacticaseibacillus paracasei (formerly Lactobacillus paracasei), Lacticaseibacillus rhamnosus (formerly Lactobacillus rhamnosus), Lactiplantibacillus pentosus Lactobacillus pentosus (formerly known as Lactobacillus pentosus), Lactiplantibacillus plantarum (formerly known as Lactobacillus plantarum), Lactobacillus acidophilusLactobacillus acidophilus), Lactobacillus delbrueckii (formerly known as Lactobacillus lactis), Lentilactobacillus hilgardii (formerly known as Lactobacillus hilgardii), Lentilactobacillus kefiri (formerly known as Lactobacillus kefiri), Levilactobacillus brevis (formerly known as Lactobacillus brevis), Limosilactobacillus fermentum (formerly known as Lactobacillus fermentum) fermentum), Limosilactobacillus reuteri (formerly Lactobacillus reuteri), Loigolactobacillus coryniformis (formerly Lactobacillus coryniformis), Lactococcus lactis (formerly Lactobacillus xylosus), Leuconostoc cremoris, Leuconostoc mesenteroides, Leuconostoc pseudomesenteroides, Pediococcus acidilactici (acidilactici), Pediococcus damnosus, Pediococcus pentosaceus, Saccharomyces bulariiThis includes probiotic organisms selected from *Streptococcus boulardii*, *Streptococcus lactis*, *Streptococcus thermophilus*, *Weissella cibaria* (formerly known as *Lactobacillus coprophilus*), and *Yarrowia lipolytica*.

[0027] Additional genetic modifications are introduced to enhance the expression and functionality of the telomerase enzyme in the claimed composition. These modifications include nucleic acid sequences encoding transcription factors that control the expression of the telomerase gene, thereby ensuring that the enzyme is produced efficiently and effectively within the probiotic strain.

[0028] The probiotic composition may be formulated into a pharmaceutical composition, incorporating a pharmaceutically acceptable carrier to ensure safety and efficacy. This formulation is designed for diverse routes of administration, such as topical, oral, or rectal use, providing flexibility to meet various therapeutic needs and preferences. Stabilizers are also included to enhance the viability of the probiotic organisms during storage and administration, ensuring that the live bacteria remain active and effective in delivering telomerase enzymes to the host. The composition may also contain subunits that further enhance enzyme expression, which may be encapsulated in capsule form (as powder) or formulated into cultured fermentations of foods or beverages (such as sour cream, fermented pickles, apple cider vinegar, and yogurt), providing convenience and ease of incorporation into daily life. A protein subunit is a polypeptide chain or a single protein molecule that associates or "co-associates" with other molecules to form a protein complex.

[0029] For oral administration, the main challenge is protecting the probiotic organism so that it can pass through the acidic gastric environment to reach the intestines, where it can effectively colonize and express telomerase. This is typically addressed by employing advanced encapsulation techniques, such as microencapsulation or the use of enteric coatings that dissolve only at the higher pH levels found in the intestines. This formulation can be complemented with prebiotics to promote and enhance the survival and activity of the probiotics, thus ensuring their maximum therapeutic potential.

[0030] For topical administration, formulation strategies focus on enabling probiotics and telomerase enzymes to penetrate the skin barrier. This often involves the use of delivery systems such as liposomes or hydrogels, which can facilitate absorption through the skin layers. Such formulations aim not only to maintain the viability of probiotics on the skin surface but also to ensure the stability and bioactivity of secreted telomerase, potentially supporting skin health and anti-aging efforts.

[0031] For rectal administration, this composition is typically prepared in the form of suppositories or enemas that can deliver probiotics directly to the lower gastrointestinal tract. These formulations are designed to ensure that the contents are released at body temperature upon insertion, placing the probiotics very close to the target site. This route can be particularly effective in achieving high local concentrations of probiotics, thereby enhancing their establishment and therapeutic activity. Across all these administration methods, the formulation is carefully designed to include stabilizers, preservatives, and nutrients that support the viability and functionality of the probiotics. Buffers may also be incorporated to maintain an optimal pH for the survival and activity of the probiotics.

[0032] The stabilizers used in the claimed compositions ensure that the biological components maintain their viability, activity, and structural integrity from the time of manufacture to administration. Polyols and sugars such as trehalose, sorbitol, and mannitol function as osmotic protectants. They shield proteins and cell membranes from dehydration and protect them from osmotic stress during freeze-drying and storage. Proteins such as skim milk, gelatin, and soy protein act as protectants for probiotic cells and enzymes, forming a protective barrier that mitigates damage through the processes of freeze, dry, and rehydrate. Glycerol, used as an antifreeze in liquid formulations, protects cells and enzymes from freeze and thaw damage by minimizing ice crystal formation and stabilizing cell membranes. Microencapsulation materials, including polymers such as alginates, chitosan, and polylactic acid-coglycolic acid (PLGA), provide a physical barrier around probiotic cells or enzymes. This barrier not only protects against environmental stresses such as pH and enzymatic degradation, but also enables controlled release at the target site. Antioxidants such as ascorbic acid (vitamin C) and tocopherol (vitamin E) are added to the formulation to prevent oxidative damage to probiotic cells and enzymes that could lead to the degradation and loss of activity of cellular components. Buffers such as phosphate buffer, citrate buffer, or acetate buffer maintain an optimal pH range, which is crucial for the stability and activity of probiotics and enzymes. This is because extreme pH levels can denature proteins and disrupt cell membranes. Finally, lyophilization protectants containing lactose and sucrose are used in the lyophilization process. They protect the structure and function of probiotic cells and enzymes during lyophilization and subsequent rehydration.

[0033] In approaches to enhance telomerase expression through recombinant probiotic organisms, enzyme-enhancing subunits play a crucial role. These components are precisely engineered genetic or molecular adducts designed to increase the production level of the telomerase enzyme within the host organism. Enzyme enhancement via such subunits involves genetic engineering strategies aimed at increasing the activity of telomerase, a key factor that can lengthen telomeres and improve cell lifespan. This concept involves incorporating specific promoter sequences into the probiotic DNA. These sequences function as critical starting points for the transcription process, acting as docking sites for RNA polymerase and other transcription factors, thereby determining the rate at which genes are transcribed into messenger RNA (mRNA). Using potent and constitutively active promoters can lead to a significant increase in telomerase expression levels, ensuring efficient transcription.

[0034] Alongside promoters, enhancer sequences play a crucial role. These DNA elements may be positioned at different distances from the genes they control, thereby binding to specific proteins that interact with the transcription mechanism. This interaction amplifies the transcription rate of the telomerase gene and thus increases enzyme production. Regulatory elements are also important, providing precision to how telomerase expression is regulated within the host. These sequences allow for the regulation of enzyme production based on environmental cues or specific internal conditions, ensuring that telomerase is produced in a temporally and spatially appropriate manner. Furthermore, codon optimization is a strategy of adjusting gene sequences to match the codon-use preferences of the host organism, thereby improving the efficiency of the translation process. This adjustment ensures that messenger RNA is more efficiently translated into the telomerase enzyme, thereby increasing the overall production rate.

[0035] In short, the claimed composition leverages the symbiotic relationship between humans and probiotics to provide a novel and non-invasive solution to the challenge of telomere shortening, a fundamental aspect of cellular aging. By providing a detailed description of the scientific principles and methodologies employed, this specification highlights the innovative approach of the present invention to enhance health and longevity through the maintenance of telomere length.

[0036] While this subject matter is described in a language specific to structural features and / or methodological actions, it should be understood that the subject matter as defined in the attached patent claims is not necessarily limited to the specific features or actions described above. Rather, the specific features and actions described above are disclosed as exemplary forms for carrying out the patent claims. [Explanation of symbols]

[0037] 100 compositions 102 Container 104 Removable top 200 capsules 202 Container 204 Removable top 300 capsules 302 Part 1 304 Part 2 402 Sour Cream 404 Fermented Pickles 406 Yogurt 408 Apple Cider Vinegar

Claims

1. A composition comprising recombinant probiotic organisms engineered to constitutively express enzymes involved in maintaining telomere length, a) The enzyme comprises a telomerase subunit, b) The genetic modification includes an operon comprising gene sequences encoding a promoter and telomerase recognized by the RNA polymerase of the probiotic organism, c) The bacteria include genetic modifications that induce the secretion of telomerase into the host organism, d) A composition in which genetic modification of the telomerase gene sequence enhances the entry of the telomerase enzyme into the cells of the host organism.

2. The composition according to claim 1, wherein the genetic modification comprises one or more nucleic acid sequences encoding a transcription factor that controls the expression of the telomerase gene in the probiotic organism.

3. The aforementioned probiotic organisms include Bacillus, Bifidobacterium, Enterococcus, Escherichia, Fructilactobacillus (formerly known as Lactobacillus), Lacticaseibacillus (formerly known as Lactobacillus), Lactiplantibacillus (formerly known as Lactobacillus), and Lactobacillus (Lac Tobacillus, Lentilactobacillus (formerly known as Lactobacillus), Leviractobacillus (formerly known as Lactobacillus), Limosilactobacillus (formerly known as Lactobacillus), Loigolactobacillus (formerly known as Lactobacillus), Lactococcus (formerly known as Lactobacillus xylosus) The composition according to claim 2, belonging to a genus selected from (xylosus), Leuconostoc, Pediococcus, Saccharomyces, Streptococcus, Weissella (formerly known as Lactobacillus), and Yarrowia.

4. The aforementioned probiotic organisms include the following species: Bacillus subtilis, Bacillus amyloliquefaciens, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium longum. Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Fructilactobacillus fructivorans (formerly Lactobacillus fructivorans), Lacticaseibacillus casei (formerly Lactobacillus casei) Lactobacillus paracasei (formerly known as Lactobacillus paracasei), Lactobacillus rhamnosus (formerly known as Lactobacillus rhamnosus), Lactiplantibacillus pentosus (formerly known as Lactobacillus pentosus) Lactobacillus plantarum (formerly known as Lactobacillus plantarum), Lactobacillus acidophilusacidophilus, Lactobacillus delbrüeckii (formerly Lactobacillus lactis), Lentilactobacillus hilgardii (formerly Lactobacillus hilgardii), Lentilactobacillus kefiri (formerly Lactobacillus kefiri) Leviractobacillus brevis (formerly known as Lactobacillus brevis), Limosilactobacillus fermentum (formerly known as Lactobacillus fermentum), Limosilactobacillus reuteri (formerly known as Lactobacillus reuteri) (reuteri), Loigolactobacillus corynifolmis (formerly Lactobacillus corynifolmis), Lactococcus lactis (formerly Lactobacillus xylosus), Leuconostoc cremoris, Leuconostoc mesenteroides, Leuconostoc pseudomesenteroides Pseudomesenteroides, Pediococcus acidilactis, Pediococcus damnosus, Pediococcus pentosaceus, Saccharomyces braliiThe composition according to claim 2, selected from boulardii), Streptococcus lactis, Streptococcus thermophilus, Weissella cibaria (formerly known as Lactobacillus coprofilus), and Yarrowia lipolytica.

5. The composition according to claim 4, wherein the probiotic organism is formulated in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

6. The composition according to claim 5, wherein the pharmaceutical composition is formulated for external administration, oral administration or transrectal administration.

7. The composition according to claim 6, further comprising a stabilizer for enhancing the viability of the probiotic organism during storage and administration to the host organism.

8. The composition according to claim 7, wherein the telomerase enzyme comprises a subunit that enhances enzyme expression.

9. The composition according to claim 8, wherein the pharmaceutical composition is encapsulated in capsule form.

10. The composition according to claim 9, wherein the pharmaceutical composition is formulated into a cultured fermented product of a food or beverage.

11. A composition comprising recombinant probiotic organisms engineered to constitutively express enzymes involved in maintaining telomere length, a) The enzyme comprises a telomerase subunit, b) The genetic modification includes an operon comprising gene sequences encoding a promoter and telomerase recognized by the RNA polymerase of the probiotic organism, c) The bacteria include genetic modifications that optimize the expression of the telomerase gene, d) A composition in which genetic modification of the telomerase gene sequence enhances the entry of the telomerase enzyme into the cells of a host organism.

12. The composition according to claim 11, wherein the genetic modification comprises one or more nucleic acid sequences encoding a transcription factor that controls the expression of the telomerase gene in the probiotic strain.

13. The aforementioned probiotic organisms include Bacillus, Bifidobacterium, Enterococcus, Escherichia, Fructilactobacillus (formerly known as Lactobacillus), Lacticaseibacillus (formerly known as Lactobacillus), Lactiplantibacillus (formerly known as Lactobacillus), and Lactobacillus (Lac Tobacillus, Lentilactobacillus (formerly known as Lactobacillus), Leviractobacillus (formerly known as Lactobacillus), Limosilactobacillus (formerly known as Lactobacillus), Loigolactobacillus (formerly known as Lactobacillus), Lactococcus (formerly known as Lactobacillus xylosus) The composition according to claim 12, belonging to a genus selected from (xylosus), Leuconostoc, Pediococcus, Saccharomyces, Streptococcus, Weissella (formerly known as Lactobacillus), and Yarrowia.

14. The aforementioned probiotic organisms include the following species: Bacillus subtilis, Bacillus amyloliquefaciens, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium longum. Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Fructilactobacillus fructivorans (formerly Lactobacillus fructivorans), Lacticaseibacillus casei (formerly Lactobacillus casei) Lactobacillus paracasei (formerly known as Lactobacillus paracasei), Lactobacillus rhamnosus (formerly known as Lactobacillus rhamnosus), Lactiplantibacillus pentosus (formerly known as Lactobacillus pentosus) Lactobacillus plantarum (formerly known as Lactobacillus plantarum), Lactobacillus acidophilusacidophilus, Lactobacillus delbrüeckii (formerly Lactobacillus lactis), Lentilactobacillus hilgardii (formerly Lactobacillus hilgardii), Lentilactobacillus kefiri (formerly Lactobacillus kefiri) Leviractobacillus brevis (formerly known as Lactobacillus brevis), Limosilactobacillus fermentum (formerly known as Lactobacillus fermentum), Limosilactobacillus reuteri (formerly known as Lactobacillus reuteri) (reuteri), Loigolactobacillus corynifolmis (formerly Lactobacillus corynifolmis), Lactococcus lactis (formerly Lactobacillus xylosus), Leuconostoc cremoris, Leuconostoc mesenteroides, Leuconostoc pseudomesenteroides Pseudomesenteroides, Pediococcus acidilactis, Pediococcus damnosus, Pediococcus pentosaceus, Saccharomyces braliiThe composition according to claim 13, selected from boulardii, Streptococcus lactis, Streptococcus thermophilus, Weissella cibaria (formerly known as Lactobacillus coprofilus), and Yarrowia lipolytica.

15. The composition according to claim 14, wherein the probiotic organism is formulated in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

16. The composition according to claim 15, wherein the pharmaceutical composition is formulated for external administration, oral administration or transrectal administration.

17. The composition according to claim 16, further comprising a stabilizer for enhancing the viability of the probiotic organism during storage and administration to the host organism.

18. The composition according to claim 17, wherein the telomerase enzyme comprises a subunit that enhances enzyme expression.

19. The composition according to claim 18, wherein the pharmaceutical composition is encapsulated in capsule form.

20. The composition according to claim 19, wherein the pharmaceutical composition is formulated into a cultured fermented product of a food or beverage.

Images